RxDoctor Payments Data

Mary Smith, MD

Therapeutic Radiology · Oklahoma City, OKNPI 1114118700

Payments from drug & device makers

$4,135in general payments, 2019–2025

Across 216 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$410
  • Novartis$358
  • Merck$246
  • Incyte Corporation$213
  • Sanofi$189
  • Takeda Pharmaceuticals U.S.A., Inc.$176
  • plus $3K from 52 others

What the payments were for

  • Food & beverage$4,119100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few therapeutic radiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$288,077
Medicare patients
284
Services billed
2,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mometasone Furoate15$431
Gabapentin13$101
Tamsulosin Hcl11$99
Ondansetron OdtOndansetron11$66

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →